

# 4th International Workshop on Biology, Prevention and Treatment of Relapse after Hematopoietic Stem Cell Transplantation

RELAPSE AFTER  
HSCT 2018



[www.relapse-after-hsct.com](http://www.relapse-after-hsct.com)

## REGISTER TODAY

September 21-22, 2018

INTERCONTINENTAL CHICAGO MAGNIFICENT MILE, CHICAGO, IL



Michael Bishop  
The University of Chicago Medicine/USA

Sergio Giralt  
Memorial Sloan Kettering Cancer Center/USA

Nicolaus Kröger  
University Hospital Hamburg/DE

Alan Wayne  
Children's Hospital Los Angeles/  
USC Norris Comprehensive Cancer Center/USA

Register today for the 4th International Workshop on Biology, Prevention and Treatment of Relapse after HSCT. Relapse and disease progression are the leading causes of treatment failure for most hematologic malignancies treated with both allogeneic and autologous hematopoietic stem cell transplantation (HSCT). The planned objectives of the workshop are designed to present the latest scientific and clinical advances related to relapse after HSCT and to provide a forum for the presentation of ongoing laboratory, translational, and clinical research specifically related to this field. The educational content of this conference is relevant for medical and pediatric hematologists-oncologists, hematopoietic stem and immune cell translational and basic scientists, hematopathologists, physicians-in-training (Fellows/Residents/Post Docs), advance practice providers, pharmacists, oncology nurses and other associated allied health professionals. The workshop will feature internationally recognized speakers from a multidisciplinary, diverse group comprised of basic and translational scientists and clinical investigators.

The Organizing Committee has been working hard to make the Fourth International Workshop a truly valuable experience for all participants. We look forward to welcoming you to the beautiful city of Chicago.

## TOPICS

### Epidemiology of relapse

### Biology of relapse

- Microenvironment
- Checkpoint blockade
- HLA-loss
- T-cell impairment
- NK/CIK cells
- Intrinsic tumor resistance

### Methods to prevent and treat relapse

- Tumor-specific T-cells
- Checkpoint inhibitors
- Genetically modified T-cells
- CAR T-cells
- NK/CIK cells
- Vaccination
- Antibodies (e.g., bispecific and polyclonal)
- Hypomethylating agents
- HDAC inhibitors
- Immunomodulating drugs (ImiDs)
- Small molecular and TKIs

### Role of minimal residual disease

- FACS
- Next Generation Sequencing
- Digital PCR

### Clinical results and trials

- Lymphoid Malignancies
- Acute Leukemias
- Multiple Myeloma
- MDS and MPN



This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Chicago Pritzker School of Medicine and the Organizing Committee. The University of Chicago Pritzker School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

The University of Chicago Pritzker School of Medicine designates this live activity for a maximum of 14 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 14 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

The American Medical Association (AMA) has an agreement of mutual recognition of continuing medical education (CME) credit with the European Union of Medical Specialties (UEMS).

International physicians interested in converting AMA PRA Category 1 Credit™ to EACCME credit should contact the UEMS.